Element Biosciences closes $277M Series D to scale AVITI adoption

Element Biosciences/AVITI

Element closed a $277M Series D funding round to accelerate AVITI adoption and expand its multiomics platform. The round reflected strong customer demand and Element's position as the leading benchtop sequencer alternative to Illumina.